📊 STRO Key Takeaways
Is Sutro Biopharma, Inc.. (STRO) a Good Investment?
Sutro Biopharma exhibits critical financial distress with negative stockholders' equity of -$132.5M and annual operating cash burn of -$177.2M against only $58.1M in cash reserves, providing less than 4 months of runway. While revenue growth of 65.2% YoY demonstrates commercial traction, the company's massive operating losses (-$158.4M), negative net margin (-186.5%), and technically insolvent balance sheet indicate the business model is not yet viable and imminent capital restructuring is highly likely.
Why Buy Sutro Biopharma, Inc.. Stock? STRO Key Strengths
- Strong revenue growth momentum at 65.2% YoY suggests market adoption of products
- Current ratio of 2.01x indicates adequate short-term liquidity position
- Insider activity with 6 Form 4 filings in 90 days shows continued stakeholder engagement
STRO Stock Risks: Sutro Biopharma, Inc.. Investment Risks
- Negative stockholders' equity of -$132.5M indicates technical insolvency with liabilities exceeding assets
- Severe operating cash burn of -$177.2M annually with only $58.1M cash provides critical runway of ~4 months
- Operating margin of -154.5% and net margin of -186.5% with no visible path to profitability
- Likely imminent capital raise will be highly dilutive to existing shareholders
- Unsustainable cash burn rate will force restructuring or bankruptcy if revenue does not dramatically accelerate profitability
Key Metrics to Watch
- Cash runway and monthly burn rate trends
- Revenue growth sustainability and gross margin expansion potential
- Operating expense reduction progress and path to operating breakeven
- Debt refinancing capability and equity raise completion status
Sutro Biopharma, Inc.. (STRO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.01x current ratio provides a solid financial cushion.
STRO Profit Margin, ROE & Profitability Analysis
STRO vs Healthcare Sector: How Sutro Biopharma, Inc.. Compares
How Sutro Biopharma, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sutro Biopharma, Inc.. Stock Overvalued? STRO Valuation Analysis 2026
Based on fundamental analysis, Sutro Biopharma, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sutro Biopharma, Inc.. Balance Sheet: STRO Debt, Cash & Liquidity
STRO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sutro Biopharma, Inc..'s revenue has grown significantly by 66% over the 5-year period, indicating strong business expansion. The most recent EPS of $-29.40 indicates the company is currently unprofitable.
STRO Revenue Growth, EPS Growth & YoY Performance
STRO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $8.5M | -$11.5M | $-0.59 |
| Q2 2025 | $25.7M | -$11.5M | $-0.14 |
| Q1 2025 | $13.0M | -$58.2M | $-0.91 |
| Q3 2024 | $8.5M | -$38.5M | $-0.59 |
| Q2 2024 | $10.4M | -$38.5M | $-0.59 |
| Q1 2024 | $12.7M | -$50.1M | $-0.85 |
| Q3 2023 | $16.9M | -$19.5M | $-0.37 |
| Q2 2023 | $10.4M | -$26.0M | $-0.55 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sutro Biopharma, Inc.. Dividends, Buybacks & Capital Allocation
STRO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sutro Biopharma, Inc.. (CIK: 0001382101)
📋 Recent SEC Filings
❓ Frequently Asked Questions about STRO
What is the AI rating for STRO?
Sutro Biopharma, Inc.. (STRO) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are STRO's key strengths?
Claude: Strong revenue growth momentum at 65.2% YoY suggests market adoption of products. Current ratio of 2.01x indicates adequate short-term liquidity position.
What are the risks of investing in STRO?
Claude: Negative stockholders' equity of -$132.5M indicates technical insolvency with liabilities exceeding assets. Severe operating cash burn of -$177.2M annually with only $58.1M cash provides critical runway of ~4 months.
What is STRO's revenue and growth?
Sutro Biopharma, Inc.. reported revenue of $102.5M.
Does STRO pay dividends?
Sutro Biopharma, Inc.. does not currently pay dividends.
Where can I find STRO SEC filings?
Official SEC filings for Sutro Biopharma, Inc.. (CIK: 0001382101) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is STRO's EPS?
Sutro Biopharma, Inc.. has a diluted EPS of $-22.49.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is STRO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Sutro Biopharma, Inc.. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is STRO stock overvalued or undervalued?
Valuation metrics for STRO: ROE of N/A (sector avg: 15%), net margin of -186.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy STRO stock in 2026?
Our dual AI analysis gives Sutro Biopharma, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is STRO's free cash flow?
Sutro Biopharma, Inc..'s operating cash flow is $-177.2M, with capital expenditures of $763.0K. FCF margin is -173.7%.
How does STRO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -186.5% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.01 (avg: 2).